All In Biotech

NDA 018276 · Upjohn

Xanax

Alprazolam · Oral · Benzodiazepine

Novel

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Oct 16, 1981

Approved uses

2

Original approval plus efficacy supplements

Registered trials

103

8 Phase 3, 7 recruiting

FAERS reports

206,207

145,716 serious, 33,581 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . • The use of benzodiazepines, including alprazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...

What it is approved for

From the label in effect Jan 15, 2025.

Alprazolam is indicated for the: • acute treatment of generalized anxiety disorder (GAD) in adults. • treatment of panic disorder (PD), with or without agoraphobia in adults. Alprazolam is a benzodiazepine indicated for the: • Acute treatment of generalized anxiety disorder in adults. ( 1 ) • Treatment of panic disorder with or without agoraphobia in adults. ( 1 )

Mechanism: Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma‑aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 6, 1990 Supplement 17 · Efficacy
  • Oct 16, 1981 Original approval · Type 1 - New Molecular Entity
4 products under this application
  • XANAX · ALPRAZOLAM 0.5MG · TABLET, ORAL · Prescription · TE AB
  • XANAX · ALPRAZOLAM 1MG · TABLET, ORAL · Prescription · TE AB
  • XANAX · ALPRAZOLAM 0.25MG · TABLET, ORAL · Prescription · TE AB
  • XANAX · ALPRAZOLAM 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Alprazolam" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective13,712
  • nausea13,127
  • fatigue12,245
  • drug abuse11,216
  • anxiety10,362
  • headache10,157
  • pain10,015
  • toxicity to various agents9,150
  • diarrhoea9,063
  • dyspnoea8,506
  • dizziness8,059
  • completed suicide7,664

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,033
20053,587
20063,453
20073,248
20084,038
20094,902
20107,773
20117,857
20129,738
20139,564
201410,329
201514,025
201614,471
201713,446
201814,823
201915,422
202014,572
202110,483
20229,637
20238,833
20248,524
20258,392
20266,050

Recalls

2 FDA enforcement reports for this application.

  • Sep 24, 2015 · Class II · Terminated

    Subpotent Drug

  • Dec 17, 2014 · Class II · Terminated

    Subpotent Drug

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xanax (Alprazolam)

2024 spending

$13.4M

Beneficiaries

3,271

20,242 claims

Per beneficiary

$4,089

$7.78 per unit

View as table
YearSpending
2020$16,560,144
2021$15,612,424
2022$14,573,125
2023$14,077,882
2024$13,374,354

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 642 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.